Amgen Inc.’s deCode genetics unit has discovered a rare genetic variation associated with a 34 percent lower-than-average risk of heart disease. In light of this discovery, Amgen is now developing investigational therapies to achieve similar effects. Learn more about deCode’s work here.
Last Updated on May 12, 2020 by Aimed Alliance
